[Federal Register Volume 82, Number 50 (Thursday, March 16, 2017)]
[Notices]
[Page 14002]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05247]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-N-2016-4198]
Public Meeting on Patient-Focused Drug Development for
Sarcopenia; Request for Comments; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is correcting a notice
entitled ``Public Meeting on Patient-Focused Drug Development for
Sarcopenia'' that appeared in the Federal Register of December 14, 2016
(81 FR 90361). The document announced a public meeting and an
opportunity for public comment on Patient-Focused Drug Development for
Sarcopenia. The location of the meeting has changed and this document
provides the updated meeting location.
FOR FURTHER INFORMATION CONTACT: Meghana Chalasani, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240-
402-6525, FAX: 301-847-8443, [email protected].
In the Federal Register of Wednesday, December 14, 2016, in FR Doc.
2016-29998, the following correction is made:
1. On page 90361, in the second column, in the first sentence of
the ADDRESSES section, ``FDA White Oak Campus, 10903 New Hampshire
Ave., Bldg. 31 Conference Center, the Great Room, (Rm. 1503), Silver
Spring, MD 20993-0002.'' is corrected to read ``Tommy Douglas
Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903.''
Dated: March 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-05247 Filed 3-15-17; 8:45 am]
BILLING CODE 4164-01-P